http://orcid.org/0000-0003-0586-1160
References
- Myers WR . Handling missing data in clinical trials: an overview. Drug Inf J. 2000;34(2):525–533.
- Little RJ , D’Agostino R , Cohen ML , et al . The prevention and treatment of missing data in clinical trials. New Engl J Med. 2012;367(14):1355–1360.
- Lane P . Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. Pharm Stat. 2008;7(2):93–106.
- DeSouza CM , Legedza ATR , Sankoh AJ . An overview of practical approaches for handling missing data in clinical trials. J Biopharm Stat. 2009;19(6):1055–1073.
- Little RJ , Rubin DB . Statistical analysis with missing data. 2nd ed. Hoboken (NJ): John Wiley & Sons, Inc.; 2002. p. 42.
- Kaplan EL , Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–481.
- Maller RA , Zhou S . Estimating the proportion of immunes in a censored sample. Biometrika. 1992;79(4):731–739.
- Greenwood M . The natural duration of cancer. London: His Majesty's Stationery Office; 1926. p. 1–26.
- Klein JP , Moeschberger ML . Survival analysis: techniques for censored and truncated data. 2nd ed. Statistics for Biology and Health. New York: Springer-Verlag, Inc.; 2003.
- Kalbfleisch JD , Prentice RL . The statistical analysis of failure time data. 2nd ed. Hoboken (NJ): John Wiley & Sons, Inc.; 2002.
- Papay K , Xie SX , Stern M , et al . Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology. 2014;83(9):826–833.